Skip to main content

Table 2 Histopathological data and intrinsic subtypes of DCIS/IBC tumour samples included in the test-set (upper panel) and validation-set (lower panel; T = Tuebingen; M = Munich; n.d. = not done). The risk categories are calculated based on individual ROR (risk-of-recurrence) scores taking the lymph node status into account. For N0 patients, low-risk, ROR 0–40 (10-years distant recurrence rate < 10%), intermediate-risk, ROR 41–60 (10-years distant recurrence rate 11–20%), high-risk, ROR 61–100 (10-years distant recurrence rate > 20%). For N1 patients, low-risk, ROR 0–15, intermediate-risk, ROR 16–40, high-risk, ROR 41–100, Samples with an asterisk are similar to samples from the fresh frozen set

From: Progression-specific genes identified in microdissected formalin-fixed and paraffin-embedded tissue containing matched ductal carcinoma in situ and invasive ductal breast cancers

sample # Age T Grade N M ER PR HER2 PAM50 intrinsic subtype (ROR) Prosigna risk category
Histopathological data and intrinsic subtypes of DCIS/IBC tumours of the test-set
 T DCIS/IBC 1 52 pT1c G2 pN0 Mx neg neg neg luminal A (0) low
 T DCIS/IBC 2 73 pT1c G2 pN0 M0 pos pos neg luminal A (25) low
 T DCIS/IBC 3 52 pT2 G2 pN0 Mx pos pos neg luminal A (32) low
 T DCIS/IBC 4 66 pT1c G2 pN0 Mx pos neg neg luminal A (30) low
 T DCIS/IBC 5 67 pT2 G2 pN1a M0 pos pos neg luminal A (34) low
 T DCIS/IBC 6 68 pT2 G2 pN2a Mx pos pos neg luminal A (33) low
 T DCIS/IBC 7 45 pT2 G2 pN1a Mx pos pos neg luminal A (27) low
 T DCIS/IBC 8* 57 pT1 G2 pN0 M0 pos pos pos luminal A (55) intermediate
 T DCIS/IBC 9* 72 pT1c G3 pN0 M0 pos pos neg luminal B (80) high
 T DCIS/IBC 10 45 pT1c G2 pN0 M0 neg neg neg HER2-enriched (71) high
 T DCIS/IBC 11* 74 pT1c G2 pN2a M0 pos pos neg HER2-enriched (93) high
 T DCIS/IBC 12* 59 pT2 G2 pN2a M0 neg neg neg basal-like (64) high
 T DCIS/IBC 13 54 pT2 G3 pN0 M0 neg neg neg basal-like (59) intermediate
 T DCIS/IBC 14 49 pT2 G2 pN1a M0 neg neg neg n.d. n.d.
 T DCIS/IBC 15* 66 pT2 G2–3 pN0 M0 neg neg pos n.d. n.d.
Histopathological data and intrinsic subtypes of DCIS/IBC tumours of the validation-set
 M DCIS/IBC 1 51 pT1c G2 pN0 M0 pos pos neg luminal A (0) low
 M DCIS/IBC 2 62 pT1b G2 pN0 Mx pos neg neg luminal A (9) low
 M DCIS/IBC 3 58 pT1b G2 pN0 Mx pos pos neg luminal A (11) low
 M DCIS/IBC 4 45 pT1c G1 pN0 M0 pos pos neg luminal A (12) low
 M DCIS/IBC 5 62 pT1b G2 pN0 Mx pos pos neg luminal A (20) low
 M DCIS/IBC 6 67 pT1c G2 pN0 M0 pos pos neg luminal A (26) low
 M DCIS/IBC 7 45 pT1b G2 pN0 Mx pos pos neg luminal A (27) low
 M DCIS/IBC 8 63 pT1c G2 pN0 M0 pos pos neg luminal A (30) low
 M DCIS/IBC 9 45 pT1b G2 pN0 Mx pos pos neg luminal A (32) low
 M DCIS/IBC 10 59 pT1c G2 pN0 M0 pos pos neg luminal A (32) low
 M DCIS/IBC 11 68 pT1b G2 pN0 Mx pos pos neg luminal A (33) low
 M DCIS/IBC 12 54 pT1a G2 pN0 Mx pos pos neg luminal A (33) low
 M DCIS/IBC 13 61 pT1b G2 pN0 Mx pos pos neg luminal A (33) low
 M DCIS/IBC 14 60 pT1c G2 pN0 Mx pos pos neg luminal A (40) low
 M DCIS/IBC 15 65 pT1c G3 pN0 M0 pos pos neg luminal A (43) intermediate
 M DCIS/IBC 16 40 pT1c G2 pN1a M0 pos pos neg luminal A (30) low
 M DCIS/IBC 17 65 pT1c G2 pN0 M0 pos pos neg luminal A (53) intermediate
 M DCIS/IBC 18 58 pT1c G3 pN0 Mx pos pos pos luminal A (76) high
 M DCIS/IBC 19 67 pT1c G2 pN2a M0 pos pos neg luminal A (36) low
 M DCIS/IBC 20 42 pT1b G3 pN1a Mx pos pos neg luminal A (48) intermediate
 M DCIS/IBC 21 57 pT1c G3 pN0 M0 pos pos neg luminal A/B (31/58) intermediate
 M DCIS/IBC 22 51 pT1c G3 pN0 M0 pos pos neg HER2-enriched (77) high
 M DCIS/IBC 23 62 pT1c G3 pN1mi M0 pos pos pos HER2-enriched (77) high
 M DCIS/IBC 24 61 pT1c G2 pN0 M0 pos pos neg n.d. n.d.
 M DCIS/IBC 25 28 pT1b G3 pN1a Mx neg pos pos n.d. n.d.